, Volume 9, Issue 1, pp 4-5,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 16 Dec 2010

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy

This is an excerpt from the content


Grey A, Boland M, Wattie D, et al.: Prolonged antiresorptive activity of zoledronate: a randomized control trial. Gen Bone Miner Res 2010, 25:2251–2255.


Zoledronic acid (ZA) is a potent nitrogen-containing bisphosphonate with a long skeletal half-life that is administered annually by intravenous (IV) infusion. In the Horizon trial, ZA significantly reduced the risk of vertebral fracture by 70%, the risk of hip fracture by 40%, and the risk of nonvertebral fracture by 20% [1]. ZA also reduced the risk of clinical fracture by 35% and decreased mortality by 28% after hip fracture in the Recurrent Fracture Trial [2]. A combination of antifracture efficacy, low rate of adverse events, and infrequent dosing make it a desirable agent for the future.


Defining the duration of action of zoledronate and the optimal dosing interval may help reduce the cost of an effective therapy.


Andrew Grey performed a 3-year randomized placebo-controlled trial of the effects on bone tur